MTOR and renal cell carcinoma: Surgery remains the primary treatment for early-stage and locally advanced RCC.[3] Patients with advanced disease are primarily managed with tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors.